Clinical trials: Macrophage Activation Syndrome (MAS)
COVID-19, Virus Diseases
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 (COVID-19) associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation.
- Conditions
- COVID-19, Virus Diseases, Macrophage Activation Syndrome, Corona Virus Infection
- Trial name
- ESCAPE (NCT04339712)
- Testing
- Anakinra, Tocilizumab
- Where
- 17 sites in Greece
- Volunteers
- 102 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Sepsis, Macrophage Activation Syndrome
A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis
The aim of the study is to conduct one RCT of personalized immunotherapy in sepsis targeting patients who lie either on the predominantly hyper-inflammatory arm or on the predominantly hypo-inflammatory arm of the spectrum of the…
- Trial name
- PROVIDE (NCT03332225)
- Testing
- Anakinra, Recombinant human interferon-gamma
- Where
- 13 sites in Greece
- Volunteers
- 36 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis
Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS), Hemophagocytic Syndromes
- Trial name
- FERRITS (NCT02854943)
- Volunteers
- 2,623 people
- Sponsor
- Gunnar Lachmann
Human Anaplasmosis
Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace.
- Trial name
- ANARETRO (NCT07312474)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
A study designed to evaluate the efficacy, safety, immunogenicity, PK, and PD characteristics of Plonmarlimab in patients with relapsed/refractory rheumatic and immunologic disease-associated MAS, and to explore biomarkers…
- Trial name
- NCT07208058
- Testing
- Plonmarlimab
- Where
- 18 sites in China
- Volunteers
- 30 people
- Sponsor
- TJ Biopharma Co., Ltd.
Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or…
- Trial name
- NCT03827343
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Kawasaki Disease, Macrophage Activation Syndrome (MAS)
MASKd: a Study on Kawasaki Disease (KD) Complicated by Macrophage Activation Syndrome (MAS)
Kawasaki Disease (KD) is one of the most common vasculitides in childhood and represents a leading cause of acquired heart disease in developed countries.
- Trial name
- NCT07491926
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Meyer Children's Hospital IRCCS
Macrophage Activation Syndrome, Still's Disease, Adult-Onset
Assessment of Macrophage Activation syndromE in STill's Disease
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
- Conditions
- Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
- Trial name
- AMETHYST (NCT06405152)
- Testing
- Chart review
- Where
- 11 sites in United States, Canada and 5 more
- Volunteers
- 75 people
- Sponsor
- Swedish Orphan Biovitrum
COVID
Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH
SARS-CoV2 has become a pandemic disease putting an enormous burden on health care systems around the world. A considerable amount of patients require intensive care treatment for Covid-19 associated pneumonia.
- Trial name
- COVIDHLH (NCT04347460)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Dengue, Dengue With Warning Signs
Anakinra in Dengue With Hyperinflammation ( AnaDen )
This study aims to evaluate the effect of anakinra in dengue patients with hyperinflammation as compared to placebo Primary Objective: To evaluate the efficacy of Anakinra in moderate-severe dengue patients with…
- Conditions
- Dengue, Dengue With Warning Signs, Severe Dengue, Anakinra
- Trial name
- NCT05611710
- Testing
- Anakinra
- Where
- Vietnam
- Volunteers
- 160 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Macrophage Activation Syndrome
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone…
- Trial name
- NCT05137496
- Testing
- Ruxolitinib, methylprednisolone
- Volunteers
- 40 people
- Sponsor
- Beijing Friendship Hospital
Bone Marrow Failure Syndrome, Severe Aplastic Anemia
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
This study's goal is to determine the frequency and severity of acute graft versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, to determine the…
- Conditions
- Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia
- Trial name
- NCT01966367
- Testing
- CD34 Stem Cell Selection Therapy
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Diane George
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset…
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Trial name
- NCT03311854
- Testing
- Emapalumab
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- Swedish Orphan Biovitrum
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal.
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Trial name
- NCT06339177
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Macrophage Activation Syndrome
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra
The primary purpose of this study is to determine whether giving injections of anakinra is a safe and well tolerated treatment to give as an adjunct to standard prescribed treatment for patients who are admitted to the hospital…
- Trial name
- MAS (NCT02780583)
- Testing
- kineret
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Alabama at Birmingham
Macrophage Activation Syndrome
Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis
The pathophysiology of macrophage activation syndrome has been mainly studied in pediatric genetic primary forms. There is little data in secondary forms related to bacterial sepsis.
- Trial name
- SAMOKINE (NCT03721809)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Rouen
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML)
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults.
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT02061800
- Testing
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diane George
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome
Macrophage activation syndrome(MAS) is a complication of bone marrow suppression, coagulopathy and CNS dysfunction which occurs in rheumatic diseases.
- Trial name
- MAS-D (NCT01095146)
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Amrita Institute of Medical Sciences & Research Center
Macrophage Activation Syndrome
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）
The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 （rhIL-2） for MAS.
- Trial name
- NCT02569463
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Peking University People's Hospital